<DOC>
	<DOCNO>NCT01679990</DOCNO>
	<brief_summary>The objective study establish safety profile Intramuscular PLX-PAD injection evaluate clinical efficacy IC subject comprise 4 treatment group : 1 . Double treatment PLX-PAD low dose 2 . Double treatment PLX-PAD high dose 3 . Double treatment Placebo 4 . Single treatment PLX-PAD high dose additional treatment Placebo . Subjects receive assign treatment twice affect leg , within 12-weeks interval treatment . The study comprise 5 stage : Screening period 4 week , first treatment PLX-PAD placebo follow additional injection 12 week follow-up 12 month post second injection</brief_summary>
	<brief_title>Safety Efficacy Allogeneic Cells Treatment Intermittent Claudication ( IC )</brief_title>
	<detailed_description />
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Adult male female subject 45 85 year age ( inclusive ) time screen visit . Subjects diagnosis peripheral artery disease , secondary atherosclerosis , confirm one follow criterion assess screen visit : Resting anklebrachial index ( ABI ) ≤ 0.80 Resting ABI ≤ 0.90 &gt; 20 % decrease ABI rest exercise measure within 1 minute treadmill exercise Toebrachial index ( TBI ) ≤ 0.60 Lifestylelimiting , moderate severe claudication ( symptoms present stable &gt; 6 month significantly change within past 3 month prior screen ) . Evidence significant ( &gt; 50 % ) stenosis infrainguinal occlusive disease confirm documented result Duplex , MRA , CTA and/or contrast angiogram complete within 3 month prior screen . The long maximal walk distance ( MWD ) Screening Period exercise treadmill test ( ETT ) , utilize modify Gardner Protocol ( Appendix I ) , must 1 10 minute ( inclusive ) . Subjects persistent claudication symptom despite recommended exercise program feasible , despite stable dose Cilostazol , indicate . Subjects Cilostazol free least 2 week prior first ETT . Subjects receive standard care drug vascular disease include antiplatelet agent ( ) statin medication , well antihypertensive medication ( ) oral hypoglycemic agents/insulin , indicate . Signed write informed consent . Ischemic rest pain ; ulceration gangrene ( Fontaine class IIIIV ; Rutherford category 46 ) . Failed low extremity arterial reconstruction ( surgical endovascular ) sympathectomy within prior one month screening . Planned revascularization ( surgical endovascular intervention ) within 12 month screen . Lower extremity artery inflow obstruction ( define great 50 % stenosis aorta , iliac and/or common femoral artery ) . History Buerger 's disease . Uncontrolled hypertension ( define diastolic blood pressure &gt; 100 mmHg systolic blood pressure &gt; 180 mmHg screening ) . Uncontrolled diabetes define glucose control HbA1c &gt; 9 % screening . Lifethreatening ventricular arrhythmia except subject implantable cardiacdefibrillator . Serum Creatinine level &gt; 2.5mg/dl . SGPT ( ALT ) , SGOT ( AST ) &gt; 2.5 x upper limit normal range . Hemoglobin &lt; 10 g/dl . Unstable cardiovascular disease define myocardial infarction ( STEMI NSTEMI ) within 3 month prior screen , unstable angina characterize increasingly frequent episode modest exertion rest , worsen severity , prolong episode . Transient Ischemic Attack ( TIA ) /Stroke within 3 month prior screen . Subjects severe congestive heart failure symptom ( i.e . NYHA Stage III IV ) . Subjects Implant mechanical prosthetic heart valve ( ) . Pulmonary disease require supplemental oxygen treatment daily basis . Severe , active infection involve extremity ( y ) , include osteomyelitis , fasciitis , severe/purulent cellulitis . History malignancy within 5 year prior screen require chemotherapy and/or radiotherapy and/or immunotherapy , exclude basal squamous cell carcinoma skin . Exercise limited condition IC , include limited congestive heart failure , chronic pulmonary disease , angina pectoris , degenerative joint disease . Uninterrupted use warfarin nonsteroidal antiinflammatory agent ( exception ibuprofen dose 1,200 mg/day Diclofenac dose 75mg/day ) . Subjects oral anticoagulant therapy ( warfarin , dabigatran , apixaban , endoxaban rivaroxaban ) . Unless , upon primary care physician and/or Investigator 's discretion subject warfarin treatment switch Low Molecular Weight Heparin treatment ( : Clexane ) 57 day prior study treatment administration return warfarin treatment 24 hour post study treatment administration . Subjects take immunosuppressive treatment ( include high dose steroid ) . Known allergy protein product ( Bovine serum , recombinant trypsin ) use cell production process . Known sensitivity Gentamycin . Known sensitivity antihistamine drug . History hospitalization due allergic/hypersensitivity reaction substance ( e.g . Food drug ) . Medical history Human Immunodeficiency Virus ( HIV ) syphilis positivity time screen . Known active Hepatitis B , Hepatitis C infection time screen . Pregnant breastfeed woman woman childbearing age protect effective contraceptive method birth control ( double barrier , oral parenteral hormonal , intrauterine device spermicide ) . In opinion Investigator , subject unsuitable participating study . Subject currently enrol , yet complete period least 30 day since end investigational device drug trial ( ) . Subjects prior exposure gene cell base therapy . Subjects legally detain official institute .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>